- Details
- Ashish Kamat invites Stephen Williams to present on costs and survival analysis between radical cystectomy and trimodal therapy. He shares results of two studies which patients from 2002-2011 were looked at in both studies focusing on methodology/statistical analyses and the outline of outcomes. This work found that trimodal therapy had significantly worse survival, these findings persisted across...
|
- Details
- Yair Lotan discusses the advancements in the ability to detect bladder cancer and bladder cancer recurrence in the clinic with blue light cystoscopy. Until recently, the technology was only available in the OR but now, with the approval of blue light flexible cystoscopy bladder cancer surveillance can now be done in the clinic. The blue light cystoscopy with CYSVIEW is performed in the clinic to d...
|
- Details
- Anne Schuckman, MD presents the information that supports her decision to use blue light cystoscopy with CYSVIEW in the clinic. She takes us through the data of the studies and her experiences too. Biography: Anne Kathryn Schuckman, MD, Assistant Professor of Clinical Urology, Keck School of Medicine, USC, Dr. Anne Schuckman graduated from Stanford University and completed her medical training at...
|
- Details
- Thomas Powles joins Charles Ryan discuss toxicity management and the most common toxicities you see in a bladder cancer population with checkpoint inhibitor therapy. Dr. Powles covers three main areas of toxicity management which include going twice as long once you've started immunosuppressants, starting steroids at a grade two toxicity, and the need to educate our patients to put them at the hea...
|
- Details
- Neal Shore and colleague, Jonathan Rubenstein provide an update on the advances and developments that have been communicated in regards to the truly important challenge of BCG shortage for the use of patients with a high-risk non-muscle invasive bladder cancer. This is an international problem. In a previous program Neal Shore, Ashish Kamat, and Jonathan Rubenstein talked about alternative dosing...
|
- Details
- Jens Bedke, MD discusses the multimodal approach for the treatment of bladder cancer from the surgeon's perspective. While cystectomy offers the greatest benefit to most patients, Dr. Bedke emphasizes the importance of differentiating patients, tumor types and tumor grades to guide patient care. Along with the role of neoadjuvant chemotherapy, Dr. Bedke discusses treatment approaches for the varia...
|
- Details
- Thomas Powles, MD, and Charles Ryan, MD share in a discussion regarding the use of immunotherapy in the peri-operative setting for bladder cancer and the current state of immunotherapy for bladder cancer. Dr. Powles, while excited about the evolving role of immunotherapy, is less enthusiastic on the use of combination immune therapy based on recent findings. Monotherapy with either atezolizumab (A...
|
- Details
- Wassim Kassouf and Alicia Morgans discuss the role of neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) including the accuracy of clinical staging and treatments. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a Professor in the Division of Urology and Vice-Chair of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and ren...
|
- Details
- Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...
|
- Details
- Thomas Powles discusses the current state of immunotherapy in the treatment of muscle-invasive bladder cancer (MIBC) specifically in the second-line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers a long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clin...
|
